杭州三因泰医药科技

Hangzhou Sanyintai Pharmaceutical Technology is a clinical-stage biotechnology company based in China that focuses on discovering and developing innovative small molecule drugs for undruggable targets. The company utilizes a proprietary drug discovery platform to address complex biological pathways in oncology and immunology. Its lead program, SYT-803, is a novel small molecule currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Sanyintai is backed by prominent venture capital firms, including Lilly Asia Ventures and Qiming Venture Partners. The company aims to provide first-in-class or best-in-class therapeutic solutions for patients with significant unmet medical needs.